On March 7, 2022 Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, reported a significant expansion of its intellectual property (IP) portfolio associated with its core drug delivery technology platform XR-17 (Press release, Vivesto, MAR 7, 2022, View Source [SID1234611838]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

XMeNa patents have been granted in Japan, Singapore, Russia and in several other jurisdictions, protecting an improved method for the manufacturing of the unique XR-17 components.

The XMeNa patent adds to Oasmia’s broad IP portfolio and provides patent protection for the XR‑17 technology and Oasmia’s lead product Apealea (paclitaxel micellar) to 2036.

Apealea is about to be commercialized in key markets around the world and is due to be launched in the UK and Germany in H1 2022. Oasmia is committed to expanding its intellectual property portfolio which covers its existing XR-17 platform and future enhancements of the platform.

Reinhard Koenig M.D., Chief Scientific Officer of Oasmia, commented "The approval of these XMeNa patents provides protection for our XR-17 technology platform in many key territories and also provides protection for our lead product Apealea and Docetaxel Micellar in any future developments that will use the XR-17 platform."

In addition to these recently granted patents, the XMeNa patent is already approved in several major pharmaceutical markets including Europe, the US, India, and Australia.